Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer

Phase 1

Terminated

Conditions: Stage IIB Breast Cancer
Stage IIIB Breast Cancer
Triple-Negative Breast Carcinoma
HER2/Neu Negative
Progesterone Receptor Negative
Stage IIA Breast Cancer
Stage IIIC Breast Cancer
Stage IIIA Breast Cancer
Estrogen Receptor Negative

Interventions: Drug: Carboplatin
Drug: Gamma-Secretase Inhibitor RO4929097
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Pharmacological Study
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2010-11-10

Last Posted Date: 2015-09-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 14

Registration Number: NCT01238133

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers

Phase 1

Completed

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Breast Cancer
Primary Peritoneal Cancer
Endometrial Cancer

Interventions: Drug: Carboplatin
Drug: Olaparib

First Posted Date: 2010-11-09

Last Posted Date: 2019-12-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 77

Registration Number: NCT01237067

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: ISIS EIF4E Rx
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2010-11-04

Last Posted Date: 2018-06-27

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 116

Registration Number: NCT01234038

Locations: 🇵🇱
Alojzy Pawelec Provincial Hospital of Lung Diseases, Wodzislaw Slaski, Poland
🇭🇺
Semmelweis University Faculty of Medicine, Budapest, Hungary
🇵🇱
Independent Public Teaching Hospital No. 4 In Lublin, Lublin, Poland

and more 26 locations

Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux.

Phase 3

Completed

Conditions: Squamous Cell Head and Neck Carcinoma

Interventions: Drug: carboplatin
Drug: 5 fluorouracil
Radiation: radiation therapy

First Posted Date: 2010-11-03

Last Posted Date: 2019-01-18

Lead Sponsor: Groupe Oncologie Radiotherapie Tete et Cou

Target Recruit Count: 370

Registration Number: NCT01233843

Locations: 🇫🇷
GIRARD CALAIS Marie-Helene, Tours, France

Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Cervical Cancer

First Posted Date: 2010-10-28

Last Posted Date: 2013-08-26

Lead Sponsor: University of Glasgow

Target Recruit Count: 130

Registration Number: NCT01229930

Locations: 🇬🇧
Cancer Research UK and University College London Cancer Trials Centre, London, England, United Kingdom
🇬🇧
Royal Marsden - Surrey, Sutton, England, United Kingdom
🇬🇧
Leicester Royal Infirmary, Leicester, England, United Kingdom

and more 2 locations

A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Linifanib
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2010-10-21

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 12

Registration Number: NCT01225302

Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study

Phase 2

Terminated

Conditions: Squamous Cell Carcinoma of the Head and Neck
Human Papilloma Virus

Interventions: Drug: docetaxel
Drug: cisplatin
Drug: 5-FU
Radiation: IMRT
Drug: cetuximab
Drug: carboplatin

First Posted Date: 2010-10-15

Last Posted Date: 2017-12-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 7

Registration Number: NCT01221753

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian

Phase 1

Completed

Conditions: Ovarian Cancer
Primary Peritoneal Cancer
Fallopian Tube Cancer

Interventions: Drug: carboplatin
Drug: Bevacizumab
Drug: Paclitaxel

First Posted Date: 2010-10-13

Last Posted Date: 2018-02-08

Lead Sponsor: Ritu Salani

Target Recruit Count: 9

Registration Number: NCT01219777

Locations: 🇺🇸
The Ohio State University Medical Center, Columbus, Ohio, United States

Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer

Phase 1

Conditions: Primary Peritoneal Cancer
Fallopian Tube Cancer
No Prior Chemotherapy
Ovarian Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Bevacizumab

First Posted Date: 2010-10-13

Last Posted Date: 2016-10-14

Lead Sponsor: David O'Malley

Target Recruit Count: 9

Registration Number: NCT01220154

Locations: 🇺🇸
OSU Gyn Oncology at Mill Run, Hilliard, Ohio, United States

A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung

Phase 2

Completed

Conditions: Adenocarcinoma of the Lung

Interventions: Biological: Farletuzumab
Other: Placebo
Drug: Carboplatin
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2010-10-11

Last Posted Date: 2020-08-20

Lead Sponsor: Morphotek

Target Recruit Count: 130

Registration Number: NCT01218516

Locations: 🇺🇸
Clinical Trials and Research Associates, Inc., Montebello, California, United States
🇺🇸
Medical Specialists of the Palm Beaches, Deerfield Beach, Florida, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

and more 90 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy